{
  "source": "PA-Med-Nec-Nemluvio.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2371-1\nProgram Prior Authorization/Medical Necessity\nMedications Nemluvio® (nemolizumab-ilto)\nP&T Approval Date 5/2025\nEffective Date 9/1/2025\n1. Background:\nNemluvio (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the\ntreatment of adults with prurigo nodularis and for the treatment of adults and pediatric patients\n12 years of age and older with moderate to severe atopic dermatitis in combination with\ntopical corticosteroids and/or calcineurin inhibitors when the disease is not adequately\ncontrolled with topical prescription therapies.\n2. Coverage Criteriaa:\nA. Atopic Dermatitis\n1. Initial Authorization\na. Nemluvio will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance to two of the following\ntherapeutic classes of topical therapies (document drug, date of trial, and/ or\ncontraindication to medication)^:\n(a) Medium,high, or very-high potency topical corticosteroid [e.g., Elocon\n(mometasone furoate), Synalar (fluocinolone acetonide), Lidex\n(fluocinonide)]\n(b) Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic\n(tacrolimus)].*\n(c) Eucrisa (crisaborole)*\n-AND-\n(3) Patient is not receiving Nemluvio in combination with either of the following\nfor treatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(4) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. Nemluvio will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to",
    "t\n(c) Immunologist\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. Nemluvio will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Nemluvio therapy\n-AND-\n(2) Patient is not receiving Nemluvio in combination with either of the following\nfor treatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR\n(tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\n-AND-\n(3) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\n-AND-\n(4) One of the following:\n(a) Patient has achieved clear or almost clear skin\n(Authorization of Nemluvio 30mg given every 8 weeks for 12 months)\n(b) Patient has not yet achieved clear or almost clear skin\n(Authorization of Nemluvio 30mg given every 4 weeks for 6 months)\nB. Prurigo Nodularis\n1. Initial Authorization\na. Nemluvio will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n2\n(1) Diagnosis of prurigo nodularis\n-AND-\n(2) Patient has greater than or equal to 20 nodular lesions\n-AND-\n(3) History of failure, contraindication, or intolerance to previous prurigo nodularis\ntreatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors, topical\ncapsaicin)\n-AND-\n(4) Patient is not receiving Nemluvio in combination with Dupixent for treatment\nof the same indication\n-AND-\n(5) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nemluvio will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Nemluvio therapy\n-AND-\n(2) Patient is not receiving Nemluvio in combination with Dupixent for treatment\nof the same indication\n-AND-\n(3) Prescribed by one of the following:\n(a) Dermatologist\n(b) All",
    "o Nemluvio therapy\n-AND-\n(2) Patient is not receiving Nemluvio in combination with Dupixent for treatment\nof the same indication\n-AND-\n(3) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n3\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n^Tried/failed alternative(s) are supported by FDA labeling.\n* Elidel, Protopic/tacrolimus ointment, and Eucrisa require prior authorization.\nTable 1: Relative potencies of topical corticosteroids\nClass Drug Dosage Form Strength\n(%)\nAugmented betamethasone Ointment, gel 0.05\ndipropionate\nVery high\nClobetasol propionate Cream, foam, ointment 0.05\npotency\nDiflorasone diacetate Ointment 0.05\nHalobetasol propionate Cream, ointment 0.05\nAmcinonide Cream, lotion, ointment 0.1\nAugmented betamethasone Cream, lotion 0.05\ndipropionate\nBetamethasone dipropionate Cream, foam, ointment, solution 0.05\nDesoximetasone Cream, ointment 0.25\nHigh Potency Desoximetasone Gel 0.05\nDiflorasone diacetate Cream 0.05\nFluocinonide Cream, gel, ointment, solution 0.05\nHalcinonide Cream, ointment 0.1\nMometasone furoate Ointment 0.1\nTriamcinolone acetonide Cream, ointment 0.5\nBetamethasone valerate Cream, foam, lotion, ointment 0.1\nClocortolone pivalate Cream 0.1\nDesoximetasone Cream 0.05\nFluocinolone acetonide Cream, ointment 0.025\nMedium\nFlurandrenolide Cream, ointment, lotion 0.05\npotency\nFluticasone propionate Cream 0.05\nFluticasone propionate Ointment 0.005\nMometasone furoate Cream, lotion 0.1\nTriamcinolone acetonide Cream, ointment, lotion 0.1\nHydrocortisone butyrate Cream, ointment, solution 0.1\nLower-\nHydrocortisone probutate Cream 0.1\nmedium\nHydrocortisone valerate Cream, ointment 0.2\npotency\nPrednicarbate Cream 0.1\nAlclometasone dipropionate Cream, ointment 0.05\nLow potency Desonid",
    "ion 0.1\nLower-\nHydrocortisone probutate Cream 0.1\nmedium\nHydrocortisone valerate Cream, ointment 0.2\npotency\nPrednicarbate Cream 0.1\nAlclometasone dipropionate Cream, ointment 0.05\nLow potency Desonide Cream, gel, foam, ointment 0.05\nFluocinolone acetonide Cream, solution 0.01\nDexamethasone Cream 0.1\nLowest\nHydrocortisone Cream, lotion, ointment, solution 0.25, 0.5, 1\npotency\nHydrocortisone acetate Cream, ointment 0.5-1\n© 2025 UnitedHealthcare Services, Inc.\n4\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class\n• Supply limitations may be in place\n4. References:\n1. Nemluvio [package insert]. Dallas, TX: Galderma Laboratories, L.P., December 2024.\n2. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic\ndermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am\nAcad Dermatol. 2014; 71(1):116-32.\nProgram Prior Authorization/Medical Necessity - Nemluvio (nemolizumab-ilto)\nChange Control\n6/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n5"
  ]
}